Laprophan Group acquires majority stake in Rivopharm

Lead party: Laprophan S.A (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Investor view in Meridian Capital Target: Rivopharm SA (private company) · Sector: Healthcare, Biotechnology, Pharmaceuticals Transaction type: Merger/Acquisition(M&A) · Asset class: Corporate Transactions · Strategy: Strategic Majority · Instrument: Ordinary Shares (Equity) Lead investor/buyer: Laprophan S.A ·…


Lead party: Laprophan S.A (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Investor view in Meridian Capital

Target: Rivopharm SA (private company) · Sector: Healthcare, Biotechnology, Pharmaceuticals

Transaction type: Merger/Acquisition(M&A) · Asset class: Corporate Transactions · Strategy: Strategic Majority · Instrument: Ordinary Shares (Equity)

Lead investor/buyer: Laprophan S.A · Investors/buyers: Laprophan S.A

Legal advisers: not identified in the source record.

Source: announced 25 June 2026. Original announcement: mcapitalp.com.